WO2018175673A1 - Méthodes et compositions de détection et de traitement de cancer - Google Patents

Méthodes et compositions de détection et de traitement de cancer Download PDF

Info

Publication number
WO2018175673A1
WO2018175673A1 PCT/US2018/023683 US2018023683W WO2018175673A1 WO 2018175673 A1 WO2018175673 A1 WO 2018175673A1 US 2018023683 W US2018023683 W US 2018023683W WO 2018175673 A1 WO2018175673 A1 WO 2018175673A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
epicenter
transcription
sox9
composition
Prior art date
Application number
PCT/US2018/023683
Other languages
English (en)
Inventor
Elaine Fuchs
Rene Adam
Yeijing GE
Original Assignee
The Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University filed Critical The Rockefeller University
Publication of WO2018175673A1 publication Critical patent/WO2018175673A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Abstract

La présente invention concerne des compositions et des méthodes de diagnostic, de traitement de cancer et de prévention contre ce dernier chez un individu. L'invention concerne également des méthodes de criblage d'une composition qui module un épicentre souhaité.
PCT/US2018/023683 2017-03-22 2018-03-22 Méthodes et compositions de détection et de traitement de cancer WO2018175673A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762474997P 2017-03-22 2017-03-22
US62/474,997 2017-03-22
US201762481257P 2017-04-04 2017-04-04
US62/481,257 2017-04-04

Publications (1)

Publication Number Publication Date
WO2018175673A1 true WO2018175673A1 (fr) 2018-09-27

Family

ID=63584714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/023683 WO2018175673A1 (fr) 2017-03-22 2018-03-22 Méthodes et compositions de détection et de traitement de cancer

Country Status (1)

Country Link
WO (1) WO2018175673A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015775A (zh) * 2021-11-10 2022-02-08 张波 头颈鳞癌治疗分子探针及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028364A1 (en) * 2006-10-27 2010-02-04 The University Of Western Ontario Inhibition of sox9 function in the treatment of proteoglycan-associated pathophysiological conditions
US20110269691A1 (en) * 2008-08-15 2011-11-03 Hearing Vincent J Compositions and Methods for Treating Pigmentary Conditions and Melanoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028364A1 (en) * 2006-10-27 2010-02-04 The University Of Western Ontario Inhibition of sox9 function in the treatment of proteoglycan-associated pathophysiological conditions
US20110269691A1 (en) * 2008-08-15 2011-11-03 Hearing Vincent J Compositions and Methods for Treating Pigmentary Conditions and Melanoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAM ET AL.: "Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice", NATURE, vol. 521, 21 May 2015 (2015-05-21), pages 366 - 370, XP055543441 *
LOVEN ET AL.,: "SELECTIVE INHIBITION OF TUMOR ONCOGENES BY DISRUPTION OF SUPER-ENHANCERS", CELL, vol. 153, no. 2, 11 April 2013 (2013-04-11), pages 320 - 334, XP028547942 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015775A (zh) * 2021-11-10 2022-02-08 张波 头颈鳞癌治疗分子探针及应用

Similar Documents

Publication Publication Date Title
Srivastava et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade
Meyer et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma
Chen et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer
Cortes et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis
Leisegang et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation
US11912994B2 (en) Methods for reactivating genes on the inactive X chromosome
JP2019512271A (ja) Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
WO2014190035A2 (fr) Compositions et procédés d'identification, d'estimation, de prévention et de traitement du cancer à l'aide de biomarqueurs et de modulateurs d'histone h3k27me2
Zavitsanou et al. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
US20210015866A1 (en) Tissue resident memory cell profiles, and uses thereof
AU2019269318A1 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
WO2018175673A1 (fr) Méthodes et compositions de détection et de traitement de cancer
US20240067970A1 (en) Methods to Quantify Rate of Clonal Expansion and Methods for Treating Clonal Hematopoiesis and Hematologic Malignancies
US20240110230A1 (en) Biomarkers for cancer treatment
US9134315B2 (en) Use of the lactosylceramide synthase isoform B1,4GalT-V as a biomarker for cancer
US20220002429A1 (en) Tumor cell aggregation inhibitors' for treating cancer
US20140356287A1 (en) PLOD2 as a Target of Intervention for Sarcoma Metastasis
Maddipati et al. MYC controls metastatic heterogeneity in pancreatic cancer
US20210309729A1 (en) Netrin g1 as a biomarker for enhancing tumor treatment efficacy
Padhye Dissecting tumor heterogeneity in lung cancer
US20240132887A1 (en) Protein arginine methyltransferase 9 inhibitors and methods of use
US20220211848A1 (en) Modulating gabarap to modulate immunogenic cell death
US20230035748A1 (en) Methods and compositions comprising a ct20 peptide
Creasy Investigation Of The Functional Impact Of Anti-Pd-1 On Tumor-Infiltrating Lymphocytes (Til) And Mapping Of Tumor Genomic Features Relevant For Response To Til Therapy
Cai Translational mechanisms of stem cell fate regulation in epidermal oncogene tolerance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18770949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18770949

Country of ref document: EP

Kind code of ref document: A1